CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Gadoquatrane, a new gadolinium-based contrast agent (GBCA), has started Phase 3 clinical testing.
The clinical development of gadoquatrane, a promising gadolinium-based contrast agent (GBCA), has reached a crucial stage with the initiation of Phase 3 trials. These trials aim to establish the agent’s potential in offering safer MRI procedures for patients, including those diagnosed with multiple sclerosis (MS).
Key Points:
- One of the trials, Quanti CNS (NCT05915702), will compare gadoquatrane against an approved GBCA in MRI scans of approximately 390 adults with central nervous system (CNS) disorders, including multiple sclerosis (MS).
- Gadoquatrane will be tested at a dose around 60% lower than that of other GBCAs, addressing safety concerns associated with these contrast agents.
Additional Points:
- MRI scans, aided by gadolinium contrast agents, are essential in diagnosing and monitoring MS.
- Accumulation of GBCAs in the brain, leading to tissue scarring and potential toxicity, has raised concerns, especially for MS patients frequently undergoing MRI scans.
- Gadoquatrane, an extracellular macrocyclic GBCA, is structurally different from other GBCAs, suggesting improved stability and higher sensitivity, allowing for lower gadolinium doses.
- Approximately 13 million contrast-enhanced MRI procedures are performed in the United States each year.
Conclusion:
- If successful, the new GBCA gadoquatrane could revolutionize MRI procedures by potentially improving the safety profile while maintaining or enhancing diagnostic efficacy, especially for MS patients and others with CNS disorders.
Radiology Latest Posts
- Abdominal Pain in a Patient with Epistaxis, Telangiectasias, and Arteriovenous Malformations
- Lung Cancer and AI: The Time Has Come Today
- Results after Four Years of Screening for Prostate Cancer with PSA and MRI
- Cannonball Pulmonary Lesions
“The demand for innovation in medical imaging to support diagnosis of diseases, guide treatment decisions and aid in therapy planning is growing as we see an increase in chronic diseases.”
Michael Forsting, MD
Director of the Institute of Diagnostic and Interventional Radiology and Neuroradiology
University Essen
